Zespół ROHHAD u 9-letniego chłopca — opis przypadku by Kot, Karolina et al.
226
Opis przypadku/Case repOrt
Endokrynologia Polska
DOI: 10.5603/EP.a2016.0037
Tom/Volume 67; Numer/Number 1/2016
ISSN 0423–104X
Karolina Kot M.D., Department of Endocrinology and Diabetology, Children’s Memorial Health Institute, Warszawa,  
Al. Dzieci Polskich 20, 04–730 Warszawa, e-mail: kot_karolina@poczta.onet.pl
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Abstract
ROHHAD syndrome (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation) is charac-
terised by rapid-onset obesity in young children, hypoventilation, and hypothalamic and autonomic dysfunction. The exact aetiology of 
the disease remains unknown, and the number of reported cases seems to be underestimated.
We present the case of a nine-year-old male patient suspected of ROHHAD due to weight gain since early childhood, decreased height 
velocity, hypoventilation, hypodipsia, excessive perspiration, and pyrexial episodes. The presented symptoms, and laboratory and imag-
ing findings met the criteria of ROHHAD syndrome.
ROHHAD should be considered in differential diagnosis for obesity in children. Early identification of the disease prevents potential 
complications specific for the syndrome, in particular a life-threatening cardio-pulmonary arrest. Patients with ROHHAD require regular 
follow-up by a multidisciplinary team. (Endokrynol Pol 2016; 67 (2): 226–231)
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Streszczenie
ROHHAD (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation) to rzadki zespół charakteryzu-
jący się pojawiającą się we wczesnym dzieciństwie szybko narastającą otyłością, hipowentylacją oraz zaburzeniami funkcji podwzgórza 
i układu autonomicznego. Przyczyny zespołu pozostają nieznane, a diagnostyka i postawienie ostatecznego rozpoznania nastręcza wielu 
trudności. Przypuszcza się, że liczba przypadków zespołu jest znacznie niedoszacowana.
W pracy zaprezentowano pierwszy w Polsce przypadek 9-letniego pacjenta z otyłością, zwolnieniem szybkości wzrastania, zaburze-
niami oddychania, hipodypsją, nadmierną potliwością i epizodami gorączek. Całość obrazu klinicznego, wyniki badań laboratoryjnych 
i obrazowych spełniają kryteria rozpoznania zespołu ROHHAD u prezentowanego pacjenta.
Zespół ROHHAD powinien być brany pod uwagę w diagnostyce różnicowej otyłości u dzieci. Wczesne postawienie rozpoznania może 
pomóc uniknąć powikłań wpisanych w obraz zespołu i zabezpieczyć pacjenta przed najgroźniejszym z nich — czyli nagłym zatrzyma-
niem krążenia i oddechu. Pacjenci z zespołem ROHHAD wymagają wielospecjalistycznej opieki i systematycznych badań kontrolnych. 
(Endokrynol Pol 2016; 67 (2): 226–231)
Słowa kluczowe: zespół ROHHAD; otyłość; centralna hipowentylacja; dysfunkcja podwzgórza
Introduction
ROHHAD syndrome (Rapid-onset Obesity with Hypo-
thalamic Dysfunction, Hypoventilation, and Autonomic 
Dysregulation) is characterised by rapid-onset obesity 
in young children, hypoventilation, and hypothalamic 
and autonomic dysfunction [1–6]. The aetiology of the 
disease remains unknown. Genetic, epigenetic, autoim-
mune, and paraneoplastic factors are taken into account 
as possible causes of ROHHAD [1–9]. There have only 
been 76 reported cases of ROHHAD [2]. This number 
seems to be underestimated. The diagnostic criteria for 
ROHHAD include central hypoventilation appearing 
after the first year of life and one or more symptoms 
such as: rapid-onset obesity, hyperprolactinaemia, 
water balance disturbance, secondary hypothyroidism, 
growth hormone deficiency, secondary adrenal insuf-
ficiency, or delayed puberty [1].
Other symptoms consistent with ROHHAD involv-
ing the hypothalamic dysfunction include hyperphagia, 
precocious/delayed puberty, nycturia, hypodipsia, 
diabetes insipidus, hypernatraemia/hyponatraemia, 
Syndrome of Inappropriate Antidiuretic Hormone 
Secretion (SIADH), and hypersomnolence. Respiratory 
manifestations embrace sleep apnoea, cyanotic episodes 
(after swimming), reduced CO2 ventilatory response, 
alveolar hypoventilation, recurrent pneumonia, and 
respiratory failure sometimes resulting in cardiac ar-
rest. Autonomic dysregulation appears in the form 
of thermal disturbances, increased sweating, dilated 
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pupils with abnormal reaction to light, strabismus, gas-
trointestinal tract dysmotility, bradycardia, cold hands 
and feet, decreased sensitivity to pain, and tumours 
of neural crest origin. Behavioural disorders comprise 
emotional lability, depression, psychotic symptoms, 
cataplexic episodes, panic and anxiety attacks, Tourette’s 
syndrome, seizures, and delay or regression of psycho-
motor development. Type 2 diabetes mellitus, impaired 
glucose tolerance, and hypercholesterolaemia may also 
be noted in children with ROHHAD [1–5].
Case report
A nine-year-old male patient presented with obe-
sity, short stature, thermoregulatory disturbances, and 
sleep apnoea. The patient was born as the first child 
of nonconsanguineous parents, after normal vaginal 
delivery, with adequate birth weight and length. His 
Apgar score was nine, and neonatal and infancy period 
were uneventful. Since the age of four years, he dem-
onstrated weight gain, decreased height velocity, and 
sleep apnoea at the same time. At the age of five years, 
the patient underwent adenotomy due to sleep ap-
noeas. At the age of six years, he developed new symp-
toms such as hypodipsia, abdominal discomfort, and 
nocturnal pyrexial episodes up to 39 degrees Celsius, 
followed by profuse sweating. Fever episodes without 
evidence of infection were accompanied by lower body 
temperature (min. 34 degrees Celsius) during the day 
and pseudo-Reynaud’s phenomenon on his limbs. At 
the age of seven years, the patient was admitted to 
hospital due to short stature and excessive weight gain. 
Physical examination showed height below 3 pc, obesity 
(> 97 pc according to height, BMI > 97 pc) as well as 
prepubertal male sex development. Laboratory tests 
(Table I) revealed moderately increased activity of AST 
(61–84 U/L, N < 47 U/L), elevated platelet count, and 
HbA1c of 6.21% (N: 4.8–5.9%). Endocrine investigations 
showed normal adrenal and thyroid axes, failed growth 
hormone stimulation tests (max. 0.3 ng/mL), IGF-1 198 
ng/mL, low fasting insulin 1.59 µU/mL (N 2.6–24.9), as 
well as normal insulin and glucose in the oral glucose 
tolerance test (OGTT). Imaging studies showed normal 
brain and pituitary scans, and delayed bone maturation 
by about three years (according to Greulich and Pyle 
atlas). The patient was started on growth hormone 
therapy. Since then, acceleration in growth velocity 
was observed nevertheless with no effect on the body 
weight or other symptoms (Fig. 1 and 2).
During the next elective hospital admission hy-
podipsia, nycturia, and abdominal discomfort were 
observed. On physical examination obesity, scoliosis, 
profuse sweating, livedo reticularis, and pseudo-
Reynaud’s phenomenon on limbs were present. The 
patient’s hands and feet were cold and clammy. The 
cardio-respiratory system was normal, except for 
transient hypertension. On palpation, there was no 
hepatosplenomegaly or lymphadenopathy. Emotional 
lability with normal intellectual development and no 
abnormalities in neurological evaluation were ob-
served. Additional laboratory examinations revealed 
hypernatraemia (148–161 mmol/L), hypercholester-
olaemia (232 mg/dL), moderate hyperprolactinaemia 
of 73 ng/mL (N: 1.8–15.9), four-fold elevated plasma 
rennin activity, normal aldosterone, slightly elevated 
adrenaline, and VMA in urine. Chromogranin A (ChA) 
and neuron-specific enolase (NSE) were near the upper 
normal limit. Abdominal ultrasound and CT scans of the 
abdomen and thorax appeared normal. Repeated brain 
MRI revealed no lesions. MIBG scintigraphy and 99mTc-
tectreotide-scintigraphy were performed and excluded 
a tumour of neural crest origin. Echocardiography 
showed no structural and functional abnormalities. 
In 72-hour ECG, the heart rate was 56/min — 183/min 
(mean frequency — 110/min), atrio-ventricular disso-
ciation periods were observed, with no pauses > 3 s.
Tuberculosis, Borrelia, HCV, HBV, Toxoplasma gon-
dii, and active CMV were ruled out. Tissue-specific 
autoantibodies were negative, the ANA test was slightly 
positive (1:80), nailfold capillaroscopy showed regular 
capillary loops.
Retested catecholamine and metabolites in 24-hour 
urine collection were normal. Sleep apnoea was con-
firmed by episodes of haemoglobin desaturation at 
night (min. SatO2 78%, HR > 100/min.), transcutaneous 
oxygen and carbon dioxide analysis during the sleep — 
PaO2 was decreased to 60 mmHg and PaCO2 was with-
in normal limits. Polysomnogram results indicated mild 
(AHI 5.5), mixed-type sleep apnoea with an obstructive 
component of about 30%. Nasofibroscopy did not reveal 
any abnormalities, and tonsillar hypertrophy Grade 2 
was diagnosed. The patient was scheduled for a home 
ventilation program on non-invasive mask ventilation 
using positive pressure ventilation during the night and 
he underwent tonsillectomy. At one-month follow-up, 
polysomnography confirmed improvement in air pas-
sage after the operation, nevertheless AHI increased to 
6.3. Genetic studies did not confirm mutation in gene 
PHOX2B resulting in congenital central hypoventilation 
syndrome nor abnormal methylation pattern in 15q 11-
13 region specific for Prader-Willi syndrome.
At six-month follow-up visit, the parents reported 
significantly reduced frequency of fever episodes and 
sweating, hands and feet became less reddened, and 
the patient stopped gaining weight. Emotional lability, 
hypodipsia, and nycturia were still present. Further 
cardiologic evaluation (72-hour ECG) revealed episodes 
of bradycardia (minimum 45/min.) with QTc increased 
228
ROHHAD in a 9-year-old boy — clinical case Karolina Kot et al.
O
PI
S 
PR
ZY
PA
D
K
U
to 0.49. Imaging investigations remained negative for 
tumour of neural crest origin.
During the diagnostic process, the patient 
underwent a wide range of specialist examinations by 
our nephrology, oncology, rheumatology, neurology, 
cardiology, pulmonology, genetics, laryngology, and 
pulmonology teams.
Discussion
The presented symptoms, and laboratory and imag-
ing findings allowed us to diagnose our patient with 
ROHHAD. Improved general condition and reduced/ 
/diminished intensity of the observed symptoms co-
incided with the starting of non-invasive ventilation 
Table I. Symptoms and laboratory findings
Tabela I. Objawy i wyniki badań laboratoryjnych
Symptoms and laboratory findings Historical data At 6 months of observation At 14 months of observation
Rapid onset obesity BMI +3.0SD BMI +1.95SD BMI +1.35SD
Short stature –2.4 SD –1.0 SD
(at 18 months of GH therapy  
– 0.42 U/kg/week)
–0.7 SD
(at 26 months of GH therapy  
– 0.49 –0.53 U/kg/week)
Failed GH stimulation tests
Insulin Max. 0.09 ng/mL
Clonidine Max. 0.31 ng/mL
Overnight Max. 0.3 ng/mL
Hypodipsia (+) (+) (+)
Nycturia (+) (+) (+)
Hyperthermia /hypothermia 34–39 34.2–37.8 35.5–36.5
degrees of Celsius (39 degrees of Celsius  
1 ×/month)
(38.5 degrees of Celsius  
2 × 7–9-days periods)
Profuse sweating (+++) (+/++) (+/++)
(++/+++) during fever periods)
Altered colour of hands and feet (+++) (+/++) (+/++)
(++) during fever periods)
Emotional lability (+) (+) (+)
Gastrointestinal dysmotility Abdominal discomfort (–) (–)
Sleep apnoea AHI — 5.5
Obstructive sleep  
apnoea 30%
AHI — 6.3
Obstructive sleep  
apnoea (–)
Bradycardia (–) min. 56/min. (+) min.45/min. (+) min.45/min.
Hypernatremia 148–161 mmol/L  
(N: 135–145mmol/L)
144–145 mmol/L 141 mmol/L
Osmolality of blood 306–325 mOsm/kg H2O  
(N: 270–295)
294 mOsm/kg H2O 282 mOsm/kg H2O
Osmolality of urine 720–1035 mOsm/ kg H2O  
(N: 50–1400)
161 mOsm/kg H2O
Hyperprolactinaemia 73.6 ng/mL (N: 1.8–15.9) 20.1 ng/mL 24.8 ng/mL
Hypercholesterolaemia Total ch. 232 mg/dL  
(N: 105–223)
207 mg/dL 194 mg/dL
HDL 98 mg/dL
LDL 80 mg/dL
AST 78 U/L (N < 53) 59 U/L 51 U/L
ARO 36.6 ng/mL/h (N: 1.5–5.7) 5.01 ng/mL/h 5.87 ng/mL/h
VMA 8.7–8.3 mg/d
(N: 2.0–3.2)
2.7–3.0 mg/d
(2.0–3.2)
3.1–3.2 mg/d
(2.3–5.2)
Adrenalin (A) 15.4–11.3 µg/d
(N: 2.4–9)
8.7–10.7 µg/d
(2,4–9.0)
6.4–9.3µg/d
(1.3–14.5)
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support and improved airway passage. This kind of 
treatment surely prevents complications of sleep ap-
noea and cardio-pulmonary arrest. Nevertheless, the 
aetiology and pathomechanism of the disease are still 
to be determined.
ROHHAD should be considered in differential 
diagnosis for obesity in children. Identification of the 
disease is extremely difficult. Other conditions accom-
panied by obesity should be checked, such as Prader 
Willi Syndrome (PWS), Bardet-Biedel Syndrome (BBS), 
Cushing Syndrome, mutation in MC4R gene, mutation 
in POMC gene, leptin receptor gene, and Congenital 
Central Hypoventilation Syndrome (CCHS). Cardiac, 
pulmonary, rheumatologic, neuromuscular, and meta-
bolic abnormalities must be ruled out as well.
Prader-Willi Syndrome [10] (frequency 1/10,000 to 
1/30,000 live births) is in 75% cases caused by chromosome 
15q11-q13 deletion on the paternal chromosome. Symp-
toms common for ROHHAD and PWS are: rapid-onset 
obesity in early childhood, hyperphagia, short stature, 
secondary adrenal insufficiency, thermal disturbances, 
hypogonadotrophic hypogonadism, and mixed central-
obstructive type of hypoventilation. Characteristic features 
also include: feeding difficulties during infancy, hypoto-
nia, scoliosis, and learning and attention difficulties.
Bardet-Biedel Syndrome [11] (frequency in Europe 
1/160,000 live births) is a heterogenic disease caused by 
mutations in one of 16 known genes leading to defects 
in the cellular ciliary structure. Obesity appears at the 
age of 2–4 years. Other specific symptoms are: retinitis 
pigmentosa, polydactyly, syndactyly, hypogonado-
trophic hypogonadism, developmental delay, cognitive 
deficit, genitourinary malformations, cardiovascular 
abnormalities, dental abnormalities, Hirschprung’s 
disease, polydipsia, polyuria, nephrogenic diabetes 
insipidus, and diabetes mellitus.
Figure 1. Growth chart
Rycina 1. Siatka centylowa wysokości ciała
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Figure 2. Body weight (for growth) chart
Rycina 2. Siatka centylowa masy ciała
Congenital Central Hypoventilation Syndrome [12] 
(Ondine’s Curse Syndrome) is caused by mutation in 
PHOX2B gene encoding transcription factor involved in 
autonomic nervous system development. The disease is 
recognised in newborns presenting severe hypoventila-
tion requiring mechanical ventilation, with the absence 
of ventilatory response to hypercapnia and hypoxia. 
There exists a group of patients with late manifestation 
of CCHS out of the newborn period. Other autonomic 
nervous system-related symptoms are: bradycardia to 
cardiac asystoles, respiratory rate variability, thermal 
dysregulation, abnormal pupillary reactivity, sweat-
ing, swallowing difficulties, oesophageal dysmotility, 
Hirschprung’s disease, and tumours of neural crest 
origin.
Hypoventilation, autonomic dysregulation, and 
tumours of neural crest origin are common symptoms 
for ROHHAD and CCHS.
Conclusions
ROHHAD should be considered in differential diagno-
sis of obesity in children, particularly when obesity is 
followed by hypothalamic, autonomic dysregulation, 
or respiratory hypoventilation symptoms. Identifica-
tion of the disease may be difficult. Final diagnosis and 
immediate adequate treatment is crucial for patients 
threatened with cardio-pulmonary arrest, cognitive 
performance deterioration, and tumours of neural crest 
origin. Patients with ROHHAD require regular follow-
up by a multidisciplinary team.
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